P3324 - Online Case-Based Education on Ulcerative Colitis Improved Competence and Confidence in Implementing a Treat-to-Target Strategy in a Diverse Patient Population

Shari J. Dermer, PhD¹, Catherine Capparelli, MBA¹, Jennifer Bomberger, MBA², Melodie C. Narain-Blackwell, ³, Roderick Smith, MS⁴, Jason Luis Quiñones, PhD¹, Anita Afzali, MD, MPH, MHCM⁵
1Medscape Education, Newark, NJ; 2Medscape Education, West Islip, NY; 3Color of Gastrointestinal Illnesses (COGI), Bowie, MD; 4Medscape Education, New York, NY; 5Department of Internal Medicine, Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cincinnati, OH

Introduction: As the breadth of treatment options for ulcerative colitis (UC) is expanding, clinicians need to determine which patients are candidates for treatment with second-line therapy as part of a treat-to-target strategy. Moreover, patient centered care must include culturally competent shared decision-making.

Methods: Learners participated in an online case-based text activity on UC that featured 2 patient cases where participants were asked to make clinical decisions as gauged by multiple choice questions. Educational results were assessed by 3 paired pre- and post-questions and a confidence assessment question. A paired samples t-test was conducted to assess the overall number of correct responses and confidence change. A McNemar’s test was conducted to evaluate individual question level statistical significance with P < .05 considered significant. Overall educational effect was evaluated by a Cohen’s d analysis. The activity launched September 4, 2024 and data were collected November 6, 2024.

Results: We report on data from gastroenterologists (GI, n =523) and PCPs (n =1,122) who participated in the activity. There was significant improvement in selecting evidence-based UC therapies by incorporating a treat-to-target strategy with an effect size of 1.49 and 1.50, respectively for GIs and PCPs.

• Competence in applying the STRIDE-II criteria when making treatment recommendations improved by 38% among GIs (50% pre/88% post) and by 44% among PCPs (38% pre/82% post)


• Competence in selecting a UC therapy that considers a patient’s preferences and barriers improved by 57% among GIs (21% pre/76% post) and by 53% among PCPs (10% pre/63% post)


• Competence in recommending UC medication based on prior treatments, severe disease burden, and patient preferences improved by 47% among GIs (33% pre/80% post) and 63% among PCPs (13% pre/78% post)


• Confidence in implementing shared decision-making in diverse patient populations improved by 19% (31% pre/50% post) among GIs and by 9% (16% pre/25% post) among PCPs

Discussion: Case-based online education resulted in improvement in competence in integrating a treat-to-target strategy for managing UC in a diverse patient population. Moreover, confidence in implementing shared decision-making these patients.


Reference: Afzali A. Advancing Therapy in Ulcerative Colitis: A Case-Based Challenge. https://www.medscape.org/viewarticle/advancing-therapy-ulcerative-colitis-case-based-challenge-2024a1000fso.

September 4, 2024.

Disclosures:
Shari Dermer indicated no relevant financial relationships.
Catherine Capparelli indicated no relevant financial relationships.
Jennifer Bomberger: Motif Neurotech – Advisory Committee/Board Member.
Melodie Narain-Blackwell: Abbvie – Speaker. Amgen – Independent Contractor. Exact Sciences – Advisor or Review Panel Member. Genetech – Advisory Committee/Board Member. Mescape – Speaker. Pfizer – Advisory Committee/Board Member.
Roderick Smith indicated no relevant financial relationships.
Jason Luis Quiñones indicated no relevant financial relationships.
Anita Afzali: AbbVie – Advisory Committee/Board Member, Consultant, Speaker fees. Bristol Myers Squibb/Celgene – Consultant. DiaSorin – Consultant. Eli Lilly – Advisory Committee/Board Member, Consultant. Gilead – Consultant. IBD Horizons – Consultant. Johnson & Johnson – Advisory Committee/Board Member, Consultant, Speaker fees. Pfizer – Advisory Committee/Board Member, Consultant, Speaker fees. Scrubs & Heels Foundation – Advisory Committee/Board Member, Consultant, Co-Founder. Takeda – Advisory Committee/Board Member, Consultant, Speaker fees. TLL Pharmaceuticals – Consultant.

Shari J. Dermer, PhD¹, Catherine Capparelli, MBA¹, Jennifer Bomberger, MBA², Melodie C. Narain-Blackwell, ³, Roderick Smith, MS⁴, Jason Luis Quiñones, PhD¹, Anita Afzali, MD, MPH, MHCM⁵. P3324 - Online Case-Based Education on Ulcerative Colitis Improved Competence and Confidence in Implementing a Treat-to-Target Strategy in a Diverse Patient Population, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.